Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations
Burkitt’s lymphoma (BL) with TP53 mutation often has poor outcome after standard chemoimmunotherapy. Adoptive chimeric antigen receptor (CAR)-T cell therapy may be a new paradigm for treating refractory/relapsed (r/r) BL, but its therapeutic effects remain inconclusive. Here, we report a patient wit...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1127868/full |
| _version_ | 1827987845290131456 |
|---|---|
| author | Qi Zhang Xiaojian Zhu Bo Liu Yicheng Zhang Yi Xiao |
| author_facet | Qi Zhang Xiaojian Zhu Bo Liu Yicheng Zhang Yi Xiao |
| author_sort | Qi Zhang |
| collection | DOAJ |
| description | Burkitt’s lymphoma (BL) with TP53 mutation often has poor outcome after standard chemoimmunotherapy. Adoptive chimeric antigen receptor (CAR)-T cell therapy may be a new paradigm for treating refractory/relapsed (r/r) BL, but its therapeutic effects remain inconclusive. Here, we report a patient with r/r BL who failed to achieve complete remission (CR) and progressed rapidly after multiple protocol chemotherapy. The patient achieved CR with CAR19 and CAR22 T-cell cocktail therapy and obtained long-term disease-free survival after autologous hematopoietic stem cells (ASCT) and subsequential CAR19 and CAR22 T-cell cocktail therapy. The clinical evolution and genetic features of this case may provide some guidance for CAR-T therapy in overcoming relapses associated with TP53 gene mutations. |
| first_indexed | 2024-04-09T23:54:28Z |
| format | Article |
| id | doaj.art-3f3f309ab5434795ad25cf76655c4d12 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-09T23:54:28Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-3f3f309ab5434795ad25cf76655c4d122023-03-17T04:31:11ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-03-011410.3389/fimmu.2023.11278681127868Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutationsQi Zhang0Xiaojian Zhu1Bo Liu2Yicheng Zhang3Yi Xiao4Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaBurkitt’s lymphoma (BL) with TP53 mutation often has poor outcome after standard chemoimmunotherapy. Adoptive chimeric antigen receptor (CAR)-T cell therapy may be a new paradigm for treating refractory/relapsed (r/r) BL, but its therapeutic effects remain inconclusive. Here, we report a patient with r/r BL who failed to achieve complete remission (CR) and progressed rapidly after multiple protocol chemotherapy. The patient achieved CR with CAR19 and CAR22 T-cell cocktail therapy and obtained long-term disease-free survival after autologous hematopoietic stem cells (ASCT) and subsequential CAR19 and CAR22 T-cell cocktail therapy. The clinical evolution and genetic features of this case may provide some guidance for CAR-T therapy in overcoming relapses associated with TP53 gene mutations.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1127868/fullBurkitt’s lymphomaTP53 mutationsCAR-TASCTrelapsed/refractory |
| spellingShingle | Qi Zhang Xiaojian Zhu Bo Liu Yicheng Zhang Yi Xiao Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations Frontiers in Immunology Burkitt’s lymphoma TP53 mutations CAR-T ASCT relapsed/refractory |
| title | Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations |
| title_full | Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations |
| title_fullStr | Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations |
| title_full_unstemmed | Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations |
| title_short | Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations |
| title_sort | case report sandwich therapy of car t combined with asct sequential car t cell therapy with asct after remission with car t therapy caused long term survival in a patient with relapsed refractory burkitt s lymphoma with tp53 mutations |
| topic | Burkitt’s lymphoma TP53 mutations CAR-T ASCT relapsed/refractory |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1127868/full |
| work_keys_str_mv | AT qizhang casereportsandwichtherapyofcartcombinedwithasctsequentialcartcelltherapywithasctafterremissionwithcarttherapycausedlongtermsurvivalinapatientwithrelapsedrefractoryburkittslymphomawithtp53mutations AT xiaojianzhu casereportsandwichtherapyofcartcombinedwithasctsequentialcartcelltherapywithasctafterremissionwithcarttherapycausedlongtermsurvivalinapatientwithrelapsedrefractoryburkittslymphomawithtp53mutations AT boliu casereportsandwichtherapyofcartcombinedwithasctsequentialcartcelltherapywithasctafterremissionwithcarttherapycausedlongtermsurvivalinapatientwithrelapsedrefractoryburkittslymphomawithtp53mutations AT yichengzhang casereportsandwichtherapyofcartcombinedwithasctsequentialcartcelltherapywithasctafterremissionwithcarttherapycausedlongtermsurvivalinapatientwithrelapsedrefractoryburkittslymphomawithtp53mutations AT yixiao casereportsandwichtherapyofcartcombinedwithasctsequentialcartcelltherapywithasctafterremissionwithcarttherapycausedlongtermsurvivalinapatientwithrelapsedrefractoryburkittslymphomawithtp53mutations |